VANDA PHARMACEUTICALS INC. Shareholders' Equity
VANDA PHARMACEUTICALS INC. (VNDA) had Shareholders' Equity of $220.19 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $220.19M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $280.76M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $327.19M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $466.00M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $220.19M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $280.76M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $327.19M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $466.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $486.33M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $511.42M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $538.55M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $541.22M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $542.52M 10-Q · filed 2025-10-30 |
| 2024-03-31 | $544.00M 10-Q · filed 2025-10-30 |
| 2023-12-31 | $544.91M 10-K · filed 2026-02-12 |
| 2023-09-30 | $543.10M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $539.90M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $535.74M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $527.20M 10-K · filed 2026-02-12 |
| 2022-09-30 | $515.66M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $508.55M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $502.12M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $504.93M 10-K · filed 2025-02-14 |
| 2021-09-30 | $493.32M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $481.22M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $467.63M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $453.27M 10-K · filed 2024-02-08 |
| 2020-09-30 | $440.57M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $431.58M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $416.39M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $410.94M 10-K · filed 2023-02-09 |
| 2019-09-30 | $400.91M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $296.69M 10-Q · filed 2020-10-29 |
| 2019-03-31 | $278.40M 10-Q · filed 2020-10-29 |
| 2018-12-31 | $275.42M 10-K · filed 2022-02-24 |
| 2018-09-30 | $261.42M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $251.27M 10-Q · filed 2019-11-07 |
| 2018-03-31 | $241.14M 10-Q · filed 2019-11-07 |
| 2017-12-31 | $131.39M 10-K · filed 2021-02-11 |
| 2017-09-30 | $130.47M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $131.42M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $128.14M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $131.33M 10-K · filed 2020-02-26 |
| 2016-09-30 | $129.16M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $121.61M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $123.01M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $133.03M 10-K · filed 2019-02-19 |
| 2015-09-30 | $145.94M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $149.75M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $152.47M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $160.82M 10-K · filed 2018-02-15 |
| 2014-09-30 | $1.06M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $885.00K 10-Q · filed 2014-08-08 |
| 2014-03-31 | $20.98M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $44.12M 10-K · filed 2017-02-17 |
| 2013-09-30 | $50.00M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $5.03M 10-Q · filed 2013-07-31 |
| 2013-03-31 | $6.48M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $9.90M 10-K · filed 2016-02-12 |
| 2012-09-30 | $15.35M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $20.08M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $26.92M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $33.47M 10-K · filed 2015-03-13 |
| 2011-09-30 | $37.68M 10-Q · filed 2011-11-07 |
| 2011-06-30 | $39.54M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $37.73M 10-K · filed 2014-02-25 |
| 2009-12-31 | $23.03M 10-K · filed 2013-02-26 |
| 2008-12-31 | $46.02M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |